| Charles A Weinheimer, MD | |
|
2000 Hospital Dr, Mount Pleasant, SC 29464-3764 | |
| (843) 416-6295 | |
| Not Available |
| Full Name | Charles A Weinheimer |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 33 Years |
| Location | 2000 Hospital Dr, Mount Pleasant, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871538595 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 16382 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| East Cooper Medical Center | Mount pleasant, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlantic Coast Anesthesia Services Pc | 3971887167 | 90 |
News Archive
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.
Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.
New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.
When someone breaks a bone in their lower leg, the fracture can often be complex, making the healing process lengthy and involved. In these cases, it is usual for the fractured bone to be surgically stabilized using an orthopedic implant.
› Verified 8 days ago
| Entity Name | Anesthesia Services Of Charleston |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730258997 PECOS PAC ID: 5496757692 Enrollment ID: O20070131000572 |
News Archive
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.
Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.
New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.
When someone breaks a bone in their lower leg, the fracture can often be complex, making the healing process lengthy and involved. In these cases, it is usual for the fractured bone to be surgically stabilized using an orthopedic implant.
› Verified 8 days ago
| Entity Name | Atlantic Coast Anesthesia Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932641313 PECOS PAC ID: 3971887167 Enrollment ID: O20170308000291 |
News Archive
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.
Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.
New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.
When someone breaks a bone in their lower leg, the fracture can often be complex, making the healing process lengthy and involved. In these cases, it is usual for the fractured bone to be surgically stabilized using an orthopedic implant.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles A Weinheimer, MD 332 N Civitas St, Mount Pleasant, SC 29464-2796 Ph: (843) 324-7159 | Charles A Weinheimer, MD 2000 Hospital Dr, Mount Pleasant, SC 29464-3764 Ph: (843) 416-6295 |
News Archive
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.
Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.
New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.
When someone breaks a bone in their lower leg, the fracture can often be complex, making the healing process lengthy and involved. In these cases, it is usual for the fractured bone to be surgically stabilized using an orthopedic implant.
› Verified 8 days ago
James T Rawls, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Johnnie Dodds Blvd, Mount Pleasant, SC 29464 Phone: 843-881-4323 | |
Kandis G Wilcox, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1200 Johnnie Dodds Blvd, Mount Pleasant, SC 29464 Phone: 843-881-4323 |